Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.

@article{Vaidyanathan2006LackOP,
  title={Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.},
  author={Sujata Vaidyanathan and Jessica V Valencia and C Kemp and Charlie Zhao and C-K. Yeh and M-N Bizot and Jannick Denouel and Hans Armin Dieterich and William P. Dole},
  journal={International journal of clinical practice},
  year={2006},
  volume={60 11},
  pages={1343-56}
}
Aliskiren is a novel, orally active direct renin inhibitor that lowers blood pressure alone and in combination with existing antihypertensive agents. As aliskiren does not affect cytochrome P450 enzyme activities, is minimally metabolised, and is not extensively protein bound, the potential for drug interactions is predicted to be low. Four open-label studies investigated the pharmacokinetic interactions between aliskiren 300 mg and the antihypertensive drugs amlodipine 10 mg (n = 18… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

RETRACTED ARTICLE: Direct renin inhibition: clinical pharmacology

Journal of Molecular Medicine • 2008
View 7 Excerpts
Highly Influenced

Aliskiren in the management of hypertension.

American journal of cardiovascular drugs : drugs, devices, and other interventions • 2010
View 4 Excerpts
Highly Influenced

Spectrofluorimetric determination of aliskiren in dosage forms and urine.

Luminescence : the journal of biological and chemical luminescence • 2012

Similar Papers

Loading similar papers…